Abstract:
PURPOSE: A manufacturing method of non-hardened glutinous rice cake is provided to be able to distribute the rice cake for a long period of time based on storage condition by maintaining the chewy texture different from hardened glutinous rice cake after certain time has passed. CONSTITUTION: Glutinous rice is soaked in water, and the water is removed. The water removed glutinous rice is pulverized. The pulverized glutinous rice is firstly steamed. Salt and water is added to the firstly steamed glutinous rice, and the mixture is steamed for the second time. The secondly steamed glutinous rice is cooled at 51-79 deg. C, and flour is added to punch the mixture for 3-20 minutes. The punched rice cake is extruded. Water addition may be 2-20 weight%. Flour addition may be 0.08-1.0 weight%. Glutinous rice cake may be rice cake covered with bean flour, mugwort rice cake covered with bean flour, wedding rice cake covered with bean flour, rice cake covered with bean flour and bean jam, flower rice cake covered with bean flour, glutinous millet rice cake covered with bean flour, Ojangi rice cake, Sonni rice cake, glutinous nutritious rice cake, or rice ball cake. [Reference numerals] (AA) Standard manufacturing method of non-hardened glutinous rice cake; (B1,D1) Washing; (B10) Punching; (B11) Extruding; (B12,D11) Molding; (B13) Wrapping(for freezing or room temperature); (B14,D13) Product completion; (B2,D2) Soaking; (B3,D3) Draining water; (B4,D5) Primary pulverization; (B5) Primary steaming; (B6) Adding salt water; (B7) Secondary steaming; (B8) Cooling steamed dough; (B9) Adding flour; (CC) Normal manufacturing method of glutinous rice cake; (D10) Hardening; (D12) Wrapping; (D4) Adding salt; (D6) Adding water; (D7) Secondary pulverization; (D8) Steaming; (D9) Punching
Abstract:
The present invention relates to a pharmaceutical composition for preventing and treating bone metabolic diseases according to the bone metastasis of cancer cells, wherein JN-2 and ION35 which are synthesized products of chemokine ligand 10 (CXCL10) are competitively combined with the acceptor (CXCR3) of the chemokine ligand 10 (CXCL10). The chemokine ligand 10 (CXCL10) increased by the bone metastasis of cancer cells acts in osteoblasts, so that the expression of RANKL which is an important factor for the differentiation of osteoblasts is increased and the differentiation of the osteoblasts is induced, according to a prior research result. Based on the prior research result, breast cancer cells (4T1) which can be easily transferred to bone cancer cells are directly administrated into the shinbone of a mouse and the composition of the present invention is administrated into the abdominal cavity for a particular period of time. As a result, resistance against bone remodeling due to the cancer cells settled in the bones is inhibited, so that bone destruction caused by the therapeutically transferred cancer cells and metabolic diseases can be controlled and treated through the same.